DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Denintuzumab mafodotin
Denintuzumab mafodotin
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Tanibirumab (CUI C3490677) Add to Cart
2017 Immuno-Oncology Medicines in Development
Πανελλήνιο Αιματολογικό Συνέδριο 28 Annual Meeting of the Hellenic Society of Haematology Η Η Βαλκανική Ημερίδα 128 Balkan Day
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
Stembook 2018.Pdf
2018 Medicines in Development for Cancer
(INN) for Biological and Biotechnological Substances
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia Renato Bassan, Jean-Pierre Bourquin, Daniel J
Antibody Drug Conjugates: Progress, Pitfalls, and Promises
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
A61K9/51 (2006.01) — with International Search Report (Art
Antibody-Drug Conjugates in Clinical Trials for Lymphoid Malignancies and Multiple Myeloma Bo Yu1 and Delong Liu2,3*
Study Protocol-Related AE Should Be Recorded from the Time of Informed Consent
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Old and New Targets for Immunotherapy of B Cell Acute
Top View
Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens
Prescrire's Contribution to the WHO Consultation on List 112 Of
Medical Affairs Pharmacy Fellowship Director Alisha Ahmed, Pharm.D., MBA Post-Doctoral Fellow, Marketing Albany College of Pharmacy and Health Sciences Class of 2017
Study Protocol
Immunotherapy of Lymphomas
Tracks 1-13 Anas Younes, MD Select Excerpts from the Interview Tracks 3
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
IMSN Open Letter on Antibody-Drug Conjugate 2151012
The Novel CD19-Targeting Antibody-Drug Conjugate Hub4
Hematologyupdate
"The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
NHL: How Will Emerging Therapies Change the Treatment Paradigm? Pier Luigi Zinzani Institute of Hematology «L
(INN) for Biological and Biotechnological Substances
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Recent Updates for Antibody Therapy for Acute Lymphoblastic Leukemia Le Li and Ying Wang*
Current Status of Marine-Derived Compounds As Warheads in Anti-Tumor Drug Candidates
The Main Te a T Ha N
Recent Developments in Immunotherapy for Acute Lymphoblastic Leukemia
Antibody–Drug Conjugates (Adcs) for Personalized Treatment of Solid Tumors: a Review
Immunotherapy for B-Acute Lymphoblastic Leukemia by Focusing on Monoclonal Antibody and CAR- T-Cell Application
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri